<DOC>
	<DOCNO>NCT02721186</DOCNO>
	<brief_summary>The overall aim study determine effectiveness two round mass drug administration ( MDA ) dihydroartemisinin-piperaquine ( DHAp ) + single low dose ( SLD ) primaquine reduce seasonal malaria transmission Shehias consider hotspot Unguja Island , Zanzibar .</brief_summary>
	<brief_title>Effectiveness Mass Drug Administration Reducing Seasonal Malaria Transmission Zanzibar</brief_title>
	<detailed_description>Study design : This cluster-randomised control study two arm : intervention arm two round MDA dihydroartemisinin-piperaquine ( DHAp ) + single low dose ( SLD ) primaquine , control arm MDA . Study site study population : The study conduct 16 hotspot Shehias ( 8 Shehias randomly allocate arm ) , three district ( West , Central South district ) Unguja Island , Zanzibar . Hotspot Shehias [ Shehia small administrative structure Zanzibar ] define Shehias annual malaria incidence &gt; 0.8 % , calculated number confirm malaria infection notify health facility active case detection 2015 / Shehia project population 2015 . The study population include consent resident select Shehias , reach approximately 24000 people . Study implementation : Two round MDA DHAp ( D-ARTEPP , Guilin Pharmaceutical ( Shanghai ) Co. , Ltd. , China ) SLD ( 0.25mg/kg ) primaquine ( Primaquine , Remedica Ltd. , Cyprus ) conduct approximately four week apart intervention Shehias , anticipate low point malaria transmission prior onset malaria transmission associate main rain April-June 2016 . The first drug dose include DHAp SLD primaquine give supervision whenever possible ; two dos standard daily DHAp regimen take unsupervised home . Labelled packet contain three dos leave head household clear instruction individual present time household visit . Study objectives : The primary objective study determine effectiveness two round MDA DHAp + SLD primaquine reduce seasonal malaria transmission Shehias consider hotspot Unguja Island , Zanzibar . The secondary objective study include determine MDA coverage , compliance , safety one two round DHAp + SLD primaquine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Permanent temporary resident study Shehias ( i.e. , person stay select household night interview ) Provision inform consent ( refusal must record ) Age &gt; 6 month Women pregnant first trimester ( assess specific set question design exclude pregnancy ) Severe disease require immediate referral health facility hospital Concurrent antimalarial treatment time MDA last 14 day Inability take oral medication Additional exclusion criterion treatment SLD Primaquine : Pregnancy ( trimester , assess specific set question design exclude pregnancy ) Women breast feeding infant age &lt; 6months</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium</keyword>
	<keyword>Mass drug administration</keyword>
	<keyword>Malaria elimination</keyword>
	<keyword>Zanzibar</keyword>
	<keyword>Dihydroartemisinin-Piperaquine</keyword>
	<keyword>Single low dose Primaquine</keyword>
</DOC>